Markets
Companies price increases earnings
(CSA Archives/Getty Images)

With earnings season done, we know what companies are thinking

They want to raise prices. That’s a bad sign for inflation, but also a reminder of why stocks are “the best of all the poor alternatives” for investors when prices surge.

Here’s one big takeaway from the more or less complete Q2 earnings season: Corporate America is trying to pass along rising costs from the Trump administration’s tariffs in the form of higher prices.

Recent notes from analysts at both Morgan Stanley and Goldman Sachs spotlighted an uptick in chatter about price hikes during the six-week flurry of quarterly reports that essentially concluded yesterday, with AI chip giant Nvidia’s numbers.

“Tariffs have begun to weigh on margins,” wrote Goldman Sachs analysts in a note published this week. “And companies are using a variety of strategies, including renegotiating contracts with suppliers and raising consumer prices, to mitigate the impact.”

Goldman Sachs Price Chart
(Goldman Sachs)

Morgan Stanley market watchers saw the same dynamic at play, writing that during earnings season companies laid out a range of options to offset or reduce the tariff-related costs.

“Corporate America is adapting on multiple fronts (pricing, supply chain, and cost control) to cushion the impact of higher import tariffs,” they wrote. “The full effect is not yet evident and we continue to expect more firmness in goods inflation.”

They also noted that several recent, forward-looking surveys of executives suggest they intend to keep the price increases coming.

Morgan Stanley Price Increase Intentions
(Morgan Stanley)

As both research shops make clear, price increases aren’t the only tool that companies are using to offset the rising impact of tariffs.

But they are a prominent one, which matters.

It’s another strong piece of evidence that the near mythical tariff-related inflation that economic wonks have been warning about for months — but which has never quite materialized — actually remains a real economic risk.

boxes on conveyor belt
Inputs are getting pricey (Getty Images)

Producer price index highlights more risk

That’s a similar story to the one told by the most recent report on the producer price index, which measures the prices companies pay their suppliers and is considered a proxy for inflation before it reaches consumers.

When the PPI numbers came out a couple weeks back, they showed showed much higher-than-expected annual PPI inflation of 3.3% in July.

As a result, economists have since raised their expectations for the Fed’s preferred gauge of consumer price inflation in July (due out Friday morning) to 2.9%, nearly a full point above the Fed’s target of 2%.

In short, there’s a lot of evidence out there that inflation risks are building.

At the same time, the Fed, after weeks of attacks on its long-established political independence — including the Trump administration’s current attempt to dismiss key Fed official Lisa Cook — seems all but certain to cut rates at its meeting next month anyway.

(Quick aside: the last time the Fed bowed to clear political pressure like this, it helped fuel the inflationary problems of the early 1970s.)

So, what happens to stocks if we get another inflationary flare-up?

Typically, you’d expect the Fed to start raising interest rates, which tends to provide a gut punch to equity prices. That was the story of 2022, when the S&P 500 dropped 19%.

But in President Trump’s America, with a Federal Reserve potentially taking cues from the White House, it’s less certain that the Fed’s response to high inflation will be typical.

Perhaps the Fed will allow much higher inflation than it has targeted in recent decades, leaving short-term interest rates lower than expected and inflation burning much hotter.

That’s not an ideal backdrop for investment. But in such a world, stocks still might be your best bet.

That’s because owning shares of companies that can actually raise prices provides some protection for investors, and is far better than options like owning bonds or sticking your cash in the bank, where inflation erodes its value.

As a sprightly, 47-year-old Warren Buffett told Fortune magazine back 1977, amid the raging inflation of that era: “Stocks are probably still the best of all the poor alternatives in an era of inflation.”

More Markets

See all Markets
markets

With their recent surge, Intel shares just hit their highest level since the dot-com era

Intel’s surge of nearly 60% this month has the iconic American chipmaker’s stock price approaching levels last seen during the dot-com era. Bloomberg noted that shares just touched their highest intraday level since the turn of the century:

The stock rose as much as 1.5% to $69.55, topping a peak it hit on Jan. 24, 2020. The shares are up 90% this year, after soaring 84% in 2025. Intel is now roughly 8% from its all-time closing high of $74.88, established on Aug. 31, 2000.

That’s just the most recent late-’90s-era throwback we’ve been seeing in tech shares lately. Oracle is currently pacing for its best week since late 1999.

What’s even more remarkable, however, is that Intel’s forward price-to-earnings ratio today dwarfs the premiums the market was putting on the stock during the nuttiness of the dot-com mania.

That reflects the fact that the recent run-up in Intel shares is, essentially, giving the chip giant credit for a massive turnaround that hasn’t actually happened yet.

One also might wonder if the fact that Intel is partially owned by the US government means it’s more attractive — and therefore worth a higher premium — than other chipmakers without the state imprimatur.

Still, kind of startling.

markets

Eli Lilly’s GLP-1 pill hit nearly 1,400 prescriptions in first week

Eli Lilly rose after preliminary numbers cited by Wall Street analysts showed strong uptake of its new weight-loss pill.

The FDA approved Foundayo on April 1 and shipments began on April 9. In its first week, roughly 1,400 US prescriptions were written for the drug, according to IQVIA data cited by Deustche Bank analysts in a Friday note.

Novo Nordisk, Lilly’s rival in the GLP-1 market, released its GLP-1 pill earlier this year, and early signs show that it’s expanding the market, inviting patients who were turned off by weekly injections. Novo’s pill had a stronger first week than Lilly’s, with its Wegovy pill hitting 3,071 US prescriptions in the first four days after its launch on January 5.

Lilly’s pill has an advantage over Novo’s, which is that it can be taken at any time of day, with or without food. Lilly disclosed in a February regulatory filing that it had $1.5 billion worth of prelaunch inventory ready ahead of the FDA approval — which is about as much as analysts polled by FactSet expect it to sell this year.

Novo Nordisk, Lilly’s rival in the GLP-1 market, released its GLP-1 pill earlier this year, and early signs show that it’s expanding the market, inviting patients who were turned off by weekly injections. Novo’s pill had a stronger first week than Lilly’s, with its Wegovy pill hitting 3,071 US prescriptions in the first four days after its launch on January 5.

Lilly’s pill has an advantage over Novo’s, which is that it can be taken at any time of day, with or without food. Lilly disclosed in a February regulatory filing that it had $1.5 billion worth of prelaunch inventory ready ahead of the FDA approval — which is about as much as analysts polled by FactSet expect it to sell this year.

markets

Critical Metals jumps after Greenland’s government approves CRML to take majority control of the Tanbreez mining project

Critical Metals is up more than 25% in premarket trading on Friday after the critical mining company announced that it now owns 92.5% of the Tanbreez rare earth deposit following an approval from the government of Greenland.

With that latest government support, Critical Minerals added an additional 50.5% stake to its ownership, reportedly acquired from Rimbal Pty Ltd, per Bloomberg News. With access to eight heavy rare earth elements often used in consumer electronics and defense, the site is one of the world’s largest undeveloped rare earth deposits and a key source of rare earth supply outside of China, according to the company.

In Critical Metals’ press release, Chairman Tony Sage commented that the approval “removes the most significant structural overhang on the project and provides the clarity to advance Tanbreez to production with confidence,” especially as Tanbreez’s location offers a significant logistical advantage through its year-round direct shipping access, compared to rival projects.

With 92.5% of the project now vested in Critical Metals Corp., and the remainder owned by European Lithium Ltd., CRML now has full control of the project and is seeking to accelerate development there, with plans for a new international airport and a 150-tonne bulk sample program, which is slated for June 2026.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.